Click on the bolded blue text within the article to gain free access to the latest research and development updates on related drugs. The AI-designed small-molecule GLP-1 receptor agonist MDR-001, independently developed by MindRank AI, has officially entered its Phase III clinical trial, named MOBILE. This trial will enroll around 750 overweight or obese individuals in China for a 52-week study, with the primary goal of evaluating the drug's effectiveness and safety profile.

Leveraging an in-house platform with AI-driven design capabilities, MDR-001 has demonstrated significant potential as a best-in-class therapeutic option. Data released from the Phase IIb trial on June 19, 2025, revealed an average weight reduction of 10.3% after 24 weeks of treatment. Additionally, the drug exhibited a favorable safety profile and led to improvements in several cardiometabolic markers.

The MOBILE trial, a multicenter, randomized, double-blind, placebo-controlled study, will specifically assess changes in participants' body weight and various health indicators after 52 weeks of treatment. By integrating multi-platform design strategies with advanced AI technology, MDR-001 has significantly enhanced the efficiency of its research and development process.

Note: This article is provided for informational purposes only and does not constitute medical advice or treatment recommendations.